IntelGenx Gets US Patent for Montelukast Product

Pharmaceutical Investing

IntelGenx announced it received a patent allowance from the United States Patent and Trademark Office.

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced it received a patent allowance from theĀ United States Patent and Trademark Office (USPTO).
As quoted in the press release:

This film formulation patent covers Montelukast oral film formulations designed for the treatment of neuroinflammation and is intended to protect IntelGenxā€™ Montelukast VersaFilmā„¢ product.
IntelGenxā€™ new, soon to be patented Montelukast oral film technology is designed to provide increased plasma concentration as compared with an immediate release oral tablet having an identical loading of Montelukast.
ā€œThe granting of this notice of allowance for a formulation specific orange book eligible patent for our Montelukast oral film validates the innovative work carried out on this project by our talented R&D teamā€ said Horst G. Zerbe, CEO of IntelGenx. ā€œWhile expanding our overall intellectual property portfolio, this new patent also solidifies the potential long-term market exclusivity of our unique Montelukast film product.ā€

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)
Ɨ